Male Contraceptive Initiative Expands Investment into Plan A™
MCI approves additional $200K grant
NEXT Life Sciences, is announcing the continuation of a grant awarded by the Male Contraceptive Initiative (MCI), the largest 501(c)(3) non-profit in the world dedicated to advancing male contraception. Awarded in 2024, this grant provided funding over two years in support of the final development of Plan A™ for upcoming clinical trials. MCI has approved ongoing funding for the second year’s $200K of this grant; reaffirming MCI's total grant funding for the development of Plan A™to $400K. This renewed support from MCI comes alongside NEXT’s preparations to begin clinical trials in Australia in Q1 of 2025 and in the US and Canada in Q2 of 2025.
“We’re incredibly grateful to MCI for their unwavering support and belief in our mission to transform male contraception,” said NEXT Life Sciences’ CEO Darlene Walley. “Our goal is to bring this revolutionary contraceptive technology to the market to provide men with a long-lasting, reversible family planning option. This further investment from MCI into Plan A™ will accelerate our ability to progress to clinical trials and move us closer to making Plan A™ a reality.”
“NEXT Life Sciences’ Plan A is an exciting option in the non-hormonal male contraceptive field,” said MCI Executive Director Heather Vahdat, MPH. “We are pleased to continue our support of NEXT Life Sciences. Plan A™ represents an exciting step toward a shared contraceptive future and provides an innovative option for men and couples seeking long-acting, reversible birth control solutions.”
This renewed support from MCI for Plan A™ also comes on the heels of the recent appointment of Dr. Darlene Walley, an industry veteran with over 30 years of experience in building life science businesses, as the new CEO of NEXT Life Sciences. Dr. Walley is working alongside Founder and Executive Chairman of NEXT Life Sciences, L.R. Fox, to lead the company through their roadmap forward with Plan A™ and other groundbreaking reproductive health products in development.
About NEXT Life Sciences
NEXT Life Sciences, Inc. (NEXT) is modernizing reproductive healthcare with its flagship product Plan A™, a non-hormonal, long-lasting, and reversible contraceptive solution for men. NEXT’s executive management team and board members have proven track records of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at successful medical device and contraceptive companies that developed and launched products that achieved iconic status. For more information, visit https://www.nextlifesciences.org/ and https://www.planaformen.com/.
Disclaimer
All forward-looking statements are not guarantees of future performance and undue reliance should not be placed on them. Statements within this document have not been evaluated by the Food and Drug Administration. Plan A™ is currently not approved by the FDA for commercial distribution.